Healthcare
Spruce Biosciences, Inc.(SPRB)
Live Price
Offline$52.36
+7.38% today
1Y Change
+897.33%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- $80.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +47.5%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Spruce Biosciences, Inc. (SPRB) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $52.36 and up 897.3% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +47.5%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +47.5%, free cash flow +40.4% with operating margin 0.0% and ROIC -84.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPRB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +47.5%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -2.5% | -4.5% | -17.3% |
2026 Mar 9, 2026 | +25.6% | +1.1% | -1.9% | +0.1% |
2025 Nov 10, 2025 | +6.3% | -2.6% | -5.9% | -17.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPRB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SPRB Max Drawdown
-98.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SPRB and SPY.
Company Overview
Spruce Biosciences, Inc.
NASDAQ Capital Market
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
- Leadership
- Javier Szwarcberg
- IPO Date
- Oct 9, 2020
- Employees
- 20
- Street Address
- 2001 Junipero Serra Boulevard
- Mailing
- Daly City, CA, 94014
- Region
- Daly City, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 655 4168
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.0
Growth
- Revenue
- -100.0%
- EPS
- +47.5%
- Free Cash Flow
- +40.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -204.0%
- ROIC
- -84.4%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 5.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.